Circulating adipokine levels and COVID-19 severity in hospitalized patients
© 2022. The Author(s)..
BACKGROUND: Obesity is a risk factor for adverse outcomes in COVID-19, potentially driven by chronic inflammatory state due to dysregulated secretion of adipokines and cytokines. We investigated the association between plasma adipokines and COVID-19 severity, systemic inflammation, clinical parameters, and outcome of COVID-19 patients.
METHODS: In this multi-centre prospective cross-sectional study, we collected blood samples and clinical data from COVID-19 patients. The severity of COVID-19 was classified as mild (no hospital admission), severe (ward admission), and critical (ICU admission). ICU non-COVID-19 patients were also included and plasma from healthy age, sex, and BMI-matched individuals obtained from Lifelines. Multi-analyte profiling of plasma adipokines (Leptin, Adiponectin, Resistin, Visfatin) and inflammatory markers (IL-6, TNFα, IL-10) were determined using Luminex multiplex assays.
RESULTS: Between March and December 2020, 260 SARS-CoV-2 infected individuals (age: 65 [56-74] BMI 27.0 [24.4-30.6]) were included: 30 mild, 159 severe, and 71 critical patients. Circulating leptin levels were reduced in critically ill patients with a high BMI yet this decrease was absent in patients that were administered dexamethasone. Visfatin levels were higher in critical COVID-19 patients compared to non-COVID-ICU, mild and severe patients (4.7 vs 3.4, 3.0, and 3.72 ng/mL respectively, p < 0.05). Lower Adiponectin levels, but higher Resistin levels were found in severe and critical patients, compared to those that did not require hospitalization (3.65, 2.7 vs 7.9 µg/mL, p < 0.001, and 18.2, 22.0 vs 11.0 ng/mL p < 0.001).
CONCLUSION: Circulating adipokine levels are associated with COVID-19 hospitalization, i.e., the need for oxygen support (general ward), or the need for mechanical ventilation and other organ support in the ICU, but not mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
International journal of obesity (2005) - 47(2023), 2 vom: 07. Feb., Seite 126-137 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Flikweert, Antine W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adipokines |
|---|
| Anmerkungen: |
Date Completed 23.02.2023 Date Revised 24.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41366-022-01246-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350220859 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350220859 | ||
| 003 | DE-627 | ||
| 005 | 20231226044516.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41366-022-01246-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350220859 | ||
| 035 | |a (NLM)36509969 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Flikweert, Antine W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Circulating adipokine levels and COVID-19 severity in hospitalized patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2023 | ||
| 500 | |a Date Revised 24.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a BACKGROUND: Obesity is a risk factor for adverse outcomes in COVID-19, potentially driven by chronic inflammatory state due to dysregulated secretion of adipokines and cytokines. We investigated the association between plasma adipokines and COVID-19 severity, systemic inflammation, clinical parameters, and outcome of COVID-19 patients | ||
| 520 | |a METHODS: In this multi-centre prospective cross-sectional study, we collected blood samples and clinical data from COVID-19 patients. The severity of COVID-19 was classified as mild (no hospital admission), severe (ward admission), and critical (ICU admission). ICU non-COVID-19 patients were also included and plasma from healthy age, sex, and BMI-matched individuals obtained from Lifelines. Multi-analyte profiling of plasma adipokines (Leptin, Adiponectin, Resistin, Visfatin) and inflammatory markers (IL-6, TNFα, IL-10) were determined using Luminex multiplex assays | ||
| 520 | |a RESULTS: Between March and December 2020, 260 SARS-CoV-2 infected individuals (age: 65 [56-74] BMI 27.0 [24.4-30.6]) were included: 30 mild, 159 severe, and 71 critical patients. Circulating leptin levels were reduced in critically ill patients with a high BMI yet this decrease was absent in patients that were administered dexamethasone. Visfatin levels were higher in critical COVID-19 patients compared to non-COVID-ICU, mild and severe patients (4.7 vs 3.4, 3.0, and 3.72 ng/mL respectively, p < 0.05). Lower Adiponectin levels, but higher Resistin levels were found in severe and critical patients, compared to those that did not require hospitalization (3.65, 2.7 vs 7.9 µg/mL, p < 0.001, and 18.2, 22.0 vs 11.0 ng/mL p < 0.001) | ||
| 520 | |a CONCLUSION: Circulating adipokine levels are associated with COVID-19 hospitalization, i.e., the need for oxygen support (general ward), or the need for mechanical ventilation and other organ support in the ICU, but not mortality | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Adipokines |2 NLM | |
| 650 | 7 | |a Leptin |2 NLM | |
| 650 | 7 | |a Resistin |2 NLM | |
| 650 | 7 | |a Nicotinamide Phosphoribosyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.4.2.12 |2 NLM | |
| 650 | 7 | |a Adiponectin |2 NLM | |
| 700 | 1 | |a Kobold, Anneke C Muller |e verfasserin |4 aut | |
| 700 | 1 | |a van der Sar-van der Brugge, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Heeringa, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Rodenhuis-Zybert, Izabela A |e verfasserin |4 aut | |
| 700 | 1 | |a Bijzet, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Tami, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a van der Gun, Bernardina T F |e verfasserin |4 aut | |
| 700 | 1 | |a Wold, Karin I |e verfasserin |4 aut | |
| 700 | 1 | |a Huckriede, Anke |e verfasserin |4 aut | |
| 700 | 1 | |a Franke, Hildegard |e verfasserin |4 aut | |
| 700 | 1 | |a Emmen, Judith M A |e verfasserin |4 aut | |
| 700 | 1 | |a Emous, Marloes |e verfasserin |4 aut | |
| 700 | 1 | |a Grootenboers, Marco J J H |e verfasserin |4 aut | |
| 700 | 1 | |a van Meurs, Matijs |e verfasserin |4 aut | |
| 700 | 1 | |a van der Voort, Peter H J |e verfasserin |4 aut | |
| 700 | 1 | |a Moser, Jill |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of obesity (2005) |d 2000 |g 47(2023), 2 vom: 07. Feb., Seite 126-137 |w (DE-627)NLM148038131 |x 1476-5497 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2023 |g number:2 |g day:07 |g month:02 |g pages:126-137 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41366-022-01246-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2023 |e 2 |b 07 |c 02 |h 126-137 | ||